[{"id":"a44fd9da-48a5-4030-9451-0e84dbc43d2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05430386","created_at":"2022-06-24T15:56:28.883Z","updated_at":"2024-07-02T16:35:55.559Z","phase":"Phase 1","brief_title":"Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC","source_id_and_acronym":"NCT05430386","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • MET mutation • MET positive • EGFR T790M negative • EGFR mutation + MET-CEP7 fusion • MET positive + EGFR mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • MET mutation • MET positive • EGFR T790M negative • EGFR mutation + MET-CEP7 fusion • MET positive + EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ameile (aumolertinib) • dalmelitinib (HS-10241)"],"overall_status":"Recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 01/05/2022","start_date":" 01/05/2022","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-02-14"}]